These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 17377388)

  • 1. Pimecrolimus cream in repigmentation of vitiligo.
    Seirafi H; Farnaghi F; Firooz A; Vasheghani-Farahani A; Alirezaie NS; Dowlati Y
    Dermatology; 2007; 214(3):253-9. PubMed ID: 17377388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
    Dawid M; Veensalu M; Grassberger M; Wolff K
    J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study.
    Farajzadeh S; Daraei Z; Esfandiarpour I; Hosseini SH
    Pediatr Dermatol; 2009; 26(3):286-91. PubMed ID: 19706089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
    Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
    Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
    Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
    Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo.
    Coskun B; Saral Y; Turgut D
    Eur J Dermatol; 2005; 15(2):88-91. PubMed ID: 15757818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
    Hartmann A; Bröcker EB; Hamm H
    J Dtsch Dermatol Ges; 2008 May; 6(5):383-5. PubMed ID: 18042249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
    Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.
    Esfandiarpour I; Ekhlasi A; Farajzadeh S; Shamsadini S
    J Dermatolog Treat; 2009; 20(1):14-8. PubMed ID: 18608735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo.
    Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP
    Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo.
    Köse O; Arca E; Kurumlu Z
    J Dermatolog Treat; 2010 May; 21(3):133-9. PubMed ID: 20394489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects.
    Lotti T; Buggiani G; Troiano M; Assad GB; Delescluse J; De Giorgi V; Hercogova J
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S20-6. PubMed ID: 18727812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo.
    Lo YH; Cheng GS; Huang CC; Chang WY; Wu CS
    J Dermatol; 2010 Feb; 37(2):125-9. PubMed ID: 20175845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo.
    Hui-Lan Y; Xiao-Yan H; Jian-Yong F; Zong-Rong L
    Pediatr Dermatol; 2009; 26(3):354-6. PubMed ID: 19706108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo.
    Mayoral FA; Vega JM; Stavisky H; McCormick CL; Parneix-Spake A
    J Drugs Dermatol; 2007 May; 6(5):517-21. PubMed ID: 17679186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo.
    Kumaran MS; Kaur I; Kumar B
    J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):269-73. PubMed ID: 16503885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical pimecrolimus: a new horizon for vitiligo treatment?
    Sendur N; Karaman G; Saniç N; Savk E
    J Dermatolog Treat; 2006; 17(6):338-42. PubMed ID: 17853306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo.
    Bakis-Petsoglou S; Le Guay JL; Wittal R
    Br J Dermatol; 2009 Oct; 161(4):910-7. PubMed ID: 19523170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo.
    Lu-yan T; Wen-wen F; Lei-hong X; Yi J; Zhi-zhong Z
    Photodermatol Photoimmunol Photomed; 2006 Dec; 22(6):310-4. PubMed ID: 17100739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo.
    Rodríguez-Martín M; García Bustínduy M; Sáez Rodríguez M; Noda Cabrera A
    Br J Dermatol; 2009 Feb; 160(2):409-14. PubMed ID: 19016706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.